
    
      Dose escalation/PK study (Phase Ib) will follow a traditional 3+3 design with evaluable
      participants enrolled at each dose level: Cohort 1 (1000mg, BID), Cohort 2, (1000mg, TID),
      and Cohort 3 (1500 mg, TID). The food-effect study will be one-week add-on study at the
      beginning of the dose escalation/PK study. Dose expansion study (Phase 2) will proceed to
      treat at the maximum tolerated dose (MTD) up to 2 years or until tumor progression,
      unacceptable toxicity, death or participants withdrawal. Participant may continue receiving
      treatment beyond 2 years at the discretion of investigator.
    
  